Synthesis and nicotinic acetylcholine receptor in vitro and in vivo pharmacological properties of 2′-fluoro-3′-(substituted phenyl)deschloroepibatidine analogues of 2′-fluoro-3′-(4- nitrophenyl)deschloroepibatidine

Journal of Medicinal Chemistry

Volumn 55, Issue 14, 2012, Pages 6512-6522

  Ondachi, Pauline ^a   Castro, Ana ^b   Luetje, Charles W ^b   Damaj, M Imad ^c   Mascarella, S Wayne ^a   Navarro, Hernán A ^a   Carroll, F Ivy ^a  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' FLUORO 3' (4 CARBAMOYLPHENYL)DESCHLOROEPIBATIDINE; EPIBATIDINE; NICOTINE; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG; VARENICLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROPHYSIOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DOCKING; MOLECULAR MODEL; MOUSE; NONHUMAN; RAT; RECEPTOR AFFINITY; TAIL FLICK TEST; X RAY CRYSTALLOGRAPHY;

ANIMALS; BEHAVIOR, ANIMAL; BICYCLO COMPOUNDS, HETEROCYCLIC; CHEMISTRY TECHNIQUES, SYNTHETIC; ELECTROPHYSIOLOGICAL PROCESSES; HUMANS; MALE; MICE; MODELS, MOLECULAR; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; PROTEIN CONFORMATION; PYRIDINES; RECEPTORS, NICOTINIC;

EID: 84864251400     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300575y     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. Smoking &Tobacco Use Fact Sheet: Smoking Cessation (updated November (2011). http://www.cdc.gov/tobacco/ data-statistics/fact-sheets/cessation/quitting/index.htm (accessed January 2012).
2. Dwoskin, L. P.; Smith, A. M.; Wooters, T. E.; Zhang, Z.; Crooks, P. A.; Bardo, M. T. Nicotinic receptor-based therapeutics and candidates for smoking cessation Biochem. Pharmacol. 2009, 78, 732-743
3. Fowler, C. D.; Arends, M. A.; Kenny, P. J. Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice Behav. Pharmacol. 2008, 19, 461-484
4. Russo, P.; Cesario, A.; Rutella, S.; Veronesi, G.; Spaggiari, L.; Galetta, D.; Margaritora, S.; Granone, P.; Greenberg, D. S. Impact of genetic variability in nicotinic acetylcholine receptors on nicotine addiction and smoking cessation treatment Curr. Med. Chem. 2011, 18, 91-112
5. Joslyn, G.; Brush, G.; Robertson, M.; Smith, T. L.; Kalmijn, J.; Schuckit, M.; White, R. L. Chromosome 15q25.1 genetic markers associated with level of response to alcohol in humans Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 20368-20373
6. Saccone, N. L.; Wang, J. C.; Breslau, N.; Johnson, E. O.; Hatsukami, D.; Saccone, S. F.; Grucza, R. A.; Sun, L.; Duan, W.; Budde, J.; Culverhouse, R. C.; Fox, L.; Hinrichs, A. L.; Steinbach, J. H.; Wu, M.; Rice, J. P.; Goate, A. M.; Bierut, L. J. The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster affects risk for nicotine dependence in African-Americans and in European-Americans Cancer Res. 2009, 69, 6848-6856
7. Wang, H. Y.; Lee, D. H.; D'Andrea, M. R.; Peterson, P. A.; Shank, R. P.; Reitz, A. B. Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology J. Biol. Chem. 2000, 275, 5626-5632
8. Frahm, S.; Slimak, M. A.; Ferrarese, L.; Santos-Torres, J.; Antolin-Fontes, B.; Auer, S.; Filkin, S.; Pons, S.; Fontaine, J. F.; Tsetlin, V.; Maskos, U.; Ibanez-Tallon, I. Aversion to nicotine is regulated by the balanced activity of beta4 and alpha5 nicotinic receptor subunits in the medial habenula Neuron 2011, 70, 522-535
9. Gallego, X.; Molas, S.; Amador-Arjona, A.; Marks, M. J.; Robles, N.; Murtra, P.; Armengol, L.; Fernandez-Montes, R. D.; Gratacos, M.; Pumarola, M.; Cabrera, R.; Maldonado, R.; Sabria, J.; Estivill, X.; Dierssen, M. Overexpression of the CHRNA5/A3/B4 genomic cluster in mice increases the sensitivity to nicotine and modifies its reinforcing effects Amino Acids 2012, 10.1007/s00726-011-1149-y
10. Toll, L.; Zaveri, N. T.; Polgar, W. E.; Jiang, F.; Khroyan, T. V.; Zhou, W.; Xie, X. S.; Stauber, G. B.; Costello, M. R.; Leslie, F. M. AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats Neuropsychopharmacology 2012, 37, 1367-1376
11. Chatterjee, S.; Steensland, P.; Simms, J. A.; Holgate, J.; Coe, J. W.; Hurst, R. S.; Shaffer, C. L.; Lowe, J. A.; Rollema, H.; Bartlett, S. E. Partial agonists of the a3b4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats Neuropsychopharmacology 2011, 36, 603-615
12. Johnston, A. J.; Ascher, J.; Leadbetter, R.; Schmith, V. D.; Patel, D. K.; Durcan, M.; Bentley, B. Pharmacokinetic optimization of sustained-release bupropion for smoking cessation Drugs 2002, 62 (Suppl. 2) 11-24
13. Hesse, L. M.; Venkatakrishnan, K.; Court, M. H.; von Moltke, L. L.; Duan, S. X.; Shader, R. I.; Greenblatt, D. J. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants Drug Metab. Dispos. 2000, 28, 1176-1183
14. Carroll, F. I.; Ma, W.; Deng, L.; Navarro, H. A.; Damaj, M. I.; Martin, B. R. Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 3′-(substituted phenyl)epibatidine analogues. Nicotinic partial agonists J. Nat. Prod. 2010, 73, 306-312
15. Carroll, F. I.; Yokota, Y.; Ma, W.; Lee, J. R.; Brieaddy, L. E.; Burgess, J. P.; Navarro, H. A.; Damaj, M. I.; Martin, B. R. Synthesis, nicotinic acetylcholine receptor binding, and pharmacological properties of 3′-(substituted phenyl)deschloroepibatidine analogs Bioorg. Med. Chem. 2008, 16, 746-754
16. Carroll, F. I.; Ma, W.; Yokota, Y.; Lee, J. R.; Brieaddy, L. E.; Navarro, H. A.; Damaj, M. I.; Martin, B. R. Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 3′-substituted deschloroepibatidine analogues. Novel nicotinic antagonists J. Med. Chem. 2005, 48, 1221-1228
17. Carroll, F. I.; Ware, R.; Brieaddy, L. E.; Navarro, H. A.; Damaj, M. I.; Martin, B. R. Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2′-fluoro-3′-(substituted phenyl)deschloroepibatidine analogs. Novel nicotinic antagonist J. Med. Chem. 2004, 47, 4588-4594
18. Carroll, F. I.; Lee, J. R.; Navarro, H. A.; Ma, W.; Brieaddy, L. E.; Abraham, P.; Damaj, M. I.; Martin, B. R. Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2′,3′- disubstituted 5′-pyridinyl)-7-azabicyclo[2.2.1]heptanes: epibatidine analogues J. Med. Chem. 2002, 45, 4755-4761
19. Carroll, F. I.; Lee, J. R.; Navarro, H. A.; Brieaddy, L. E.; Abraham, P.; Damaj, M. I.; Martin, B. R. Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2- exo -2-(2′-substituted- 3′-phenyl-5′-pyridinyl)-7-azabicyclo[2.2.1]heptanes. Novel nicotinic antagonist J. Med. Chem. 2001, 44, 4039-4041
20. Carroll, F. I.; Liang, F.; Navarro, H. A.; Brieaddy, L. E.; Abraham, P.; Damaj, M. I.; Martin, B. R. Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2- exo -2-(2′-substituted 5′-pyridinyl)-7-azabicyclo[2.2.1]heptanes. Epibatidine analogues J. Med. Chem. 2001, 44, 2229-2237
21. Abdrakhmanova, G. R.; Damaj, M. I.; Carroll, F. I.; Martin, B. R. 2-Fluoro-3-(4-nitro-phenyl)deschloroepibatidine is a novel potent competitive antagonist of human neuronal α4β2 nAChRs Mol. Pharmacol. 2006, 69, 1945-1952
22. Tobey, K. M.; Walentiny, D. M.; Wiley, J. L.; Carroll, F. I.; Damaj, M. I.; Azar, M. R.; Koob, G. F.; George, O.; Harris, L. S.; Vann, R. E. Effects of the specific α4β2 nAChR antagonist, 2-fluoro-3-(4-nitrophenyl) deschloroepibatidine, on nicotine reward-related behaviors Psychopharmacology (Berlin) 2012, 10.1007/s00213-012-2703-3
23. Li, S. X.; Huang, S.; Bren, N.; Noridomi, K.; Dellisanti, C. D.; Sine, S. M.; Chen, L. Ligand-binding domain of an alpha7-nicotinic receptor chimera and its complex with agonist Nat. Neurosci. 2011, 14, 1253-1259
24. SYBYL-X 1.2; Tripos International: St. Louis, MO, 2012.
25. Huang, Y.; Zhu, Z.; Xiao, Y.; Laruelle, M. Epibatidine analogues as selective ligands for the alpha(x)beta2-containing subtypes of nicotinic acetylcholine receptors Bioorg. Med. Chem. Lett. 2005, 15, 4385-4388
26. Carroll, F. I. Epibatidine structure-activity relationships Bioorg. Med. Chem. Lett. 2004, 14, 1889-1896
27. Hansch, C.; Leo, A. Electronic effects on organic reactions. In Exploring QSAR: Fundamenetals and Applications in Chemistry and Biology; American Chemical Society: Washington, DC, 1995; p 7.
28. Stokes, C.; Papke, J. K.; Horenstein, N. A.; Kem, W. R.; McCormack, T. J.; Papke, R. L. The structural basis for GTS-21 selectivity between human and rat nicotinic alpha7 receptors Mol. Pharmacol. 2004, 66, 14-24
29. Coe, J. W.; Brooks, P. R.; Vetelino, M. G.; Wirtz, M. C.; Arnold, E. P.; Huang, J.; Sands, S. B.; Davis, T. I.; Lebel, L. A.; Fox, C. B.; Shrikhande, A.; Heym, J. H.; Schaeffer, E.; Rollema, H.; Lu, Y.; Mansbach, R. S.; Chambers, L. K.; Rovetti, C. C.; Schulz, D. W.; Tingley, F. D., 3rd; O'Neill, B. T. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation J. Med. Chem. 2005, 48, 3474-3477
30. Mihalak, K. B.; Carroll, F. I.; Luetje, C. W. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors Mol. Pharmacol. 2006, 70, 801-805
31. Avalos, M.; Parker, M. J.; Maddox, F. N.; Carroll, F. I.; Luetje, C. W. Effects of pyridine ring substitutions on the affinity, efficacy, and subtype selectivity of the neuronal nicotinic receptor agonist epibatidine J. Pharmacol. Exp. Ther. 2002, 302, 1246-1252
32. Jensen, A. A.; Frolund, B.; Liljefors, T.; Krogsgaard-Larsen, P. Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations J. Med. Chem. 2005, 48, 4705-4745
33. 125I]iodomethyllycaconitine in the rat Synapse 2002, 44, 117-123
34. D'Amour, F. E.; Smith, D. L. A method for determining loss of pain sensation J. Pharmacol. Exp. Ther. 1941, 72, 74-79